Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group - U1245 - Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques Access content directly
Journal Articles Clinical Pharmacokinetics Year : 2017

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

Anne-Laure Gagez
  • Function : Author
Kamel Laribi
Guillaume Cartron

Abstract

Rituximab is an anti-CD20 monoclonal antibody approved in the first-line treatment of patients with chronic lymphocytic leukemia (CLL). Rituximab pharmacokinetics shows a time dependency possibly related to changes in the target antigen amount over time. The purpose of this study was to quantify the influence of both CD20 antigenic mass and the FcγRIIIA genetic polymorphism on rituximab pharmacokinetics in CLL.

Domains

Medication
Fichier principal
Vignette du fichier
tout2016.pdf (460.99 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-01769807 , version 1 (15-01-2024)

Identifiers

Cite

Mira Tout, Anne-Laure Gagez, Stéphane Lepretre, Valérie Gouilleux-Gruart, Nicolas Azzopardi, et al.. Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group. Clinical Pharmacokinetics, 2017, 56 (6), pp.635 - 647. ⟨10.1007/s40262-016-0470-8⟩. ⟨hal-01769807⟩
75 View
5 Download

Altmetric

Share

Gmail Facebook X LinkedIn More